Health & Biotech
ASX Health Stocks: AVITA flies as high as 24pc after providing a big, bullish guidance
Health & Biotech
‘Fully funded’ – MGC Pharma completes share consolidation and ~US$8 million cap raise
Health & Biotech
ASX Health Stocks: Race Oncology gets certified for RC220; human trials next
Health & Biotech
Microcap with a Blue-Chip profile: Trajan Group is growing through key acquisitions, partnerships and collaborations
Health & Biotech
Weed Week: Jamaican nettletree could be a new, cheaper option to source CBD, says scientists
Health & Biotech
Paradigm Biopharmaceuticals is transforming the way we treat osteoarthritis
Health & Biotech
ASX Health Stocks: HeraMED jumps 30pc after maternity care platform goes live at clinical trial
Health & Biotech
Dimerix receives $10.7 million upfront payment from Advanz Pharma
Health & Biotech
ASX Health Stocks: Clarity Pharma, Island Pharma set to embark on next steps of clinical trials
Health & Biotech
Race Oncology releases ‘striking’ interim Phase 2 AML trial results
Health & Biotech
ADX Energy eyes thicker target areas at Anshof-2 to significantly increase 2P reserves and oil production
Health & Biotech
ASX Health Stocks: PYC on the same page with FDA, Cleo’s cancer test peer-reviewed
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.